Literature DB >> 25220208

Occult nodal disease in patients with non-small-cell lung cancer who are suitable for stereotactic ablative body radiation.

Jonathan M Robson1, Sriram Vaidyanathan2, Leanne Cheyne2, Michael Snee2, Kevin Franks2, Matthew E J Callister2.   

Abstract

INTRODUCTION: Stereotactic ablative body radiotherapy is a therapeutic option for patients with peripheral stage I NSCLC in whom surgical resection is considered high risk. Patients receiving SABR do not undergo systematic nodal dissection and any occult nodal metastases will therefore go undetected. Our aim was to determine what proportion of cases this might represent.
MATERIALS AND METHODS: We retrospectively studied patients who underwent lung resections for presumed stage I NSCLC between 2008 and 2011 at a United Kingdom teaching hospital. We reviewed postoperative pathological lymph node staging and analyzed a subset of these patients in whom SABR would have been be technically possible.
RESULTS: We reviewed 128 cases of presumed NSCLC preoperatively staged as T1/2a N0 M0. Of 89 cases with peripheral tumor location, 8 patients (8.9%) had nodal involvement at surgical resection.
CONCLUSION: Our data show that approximately 1 in 11 patients with peripheral stage I NSCLC will have occult mediastinal/hilar nodal involvement. Although this is a relatively small proportion, routine use of EBUS-TBNA for nodal staging in patients undergoing SABR might identify a greater proportion of patients with nodal disease compared with a strategy of nodal staging directed according to positron emission tomography-computed tomography findings.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endobronchial ultrasound; Mediastinal lymph node; Radiotherapy; Staging; Thoracic surgery

Mesh:

Year:  2014        PMID: 25220208     DOI: 10.1016/j.cllc.2014.07.006

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  5 in total

1.  Is staging mediastinoscopy necessary before stereotactic body radiotherapy for inoperable early stage lung cancer?

Authors:  Jean-Claude M Rwigema; Percy Lee
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC.

Authors:  William R Kennedy; Pamela P Samson; Prashant Gabani; John Nikitas; Jeffrey D Bradley; Michael C Roach; Clifford G Robinson
Journal:  Radiother Oncol       Date:  2020-07-03       Impact factor: 6.280

3.  Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients.

Authors:  Macarena R Vial; Kashif A Khan; Oisin O'Connell; S Andrew Peng; Daniel R Gomez; Joe Y Chang; David C Rice; Reza Mehran; Carlos J Jimenez; Horiana B Grosu; David E Ost; George A Eapen
Journal:  Ann Thorac Surg       Date:  2016-12-24       Impact factor: 4.330

Review 4.  Rationale for Combing Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung Cancer.

Authors:  Alexander Chi; Nam P Nguyen
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

5.  Clinical significance of PET/CT uptake for peripheral clinical N0 non-small cell lung cancer.

Authors:  Shuai Wang; Dong Lin; Xiaodong Yang; Cheng Zhan; Shihai Zhao; Rongkui Luo; Qun Wang; Lijie Tan
Journal:  Cancer Med       Date:  2020-02-13       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.